VH sdAbs Anchor Therapeutics to PD-1 Without Ligand Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based therapies for cancer treatment, particularly targeting the PD-1 pathway, often block the interaction between PD-1 and its ligands, which can lead to unintended suppression of T-cell activity, and there is a need for alternative treatments that can modulate immune responses without blocking this interaction.
Innovation Solution
Development of human variable single domain antibodies (VH sdAbs) that bind to PD-1 without blocking its interaction with PD-L1 and PD-L2, allowing for anchoring of therapeutic molecules to PD-1 and potentially enhancing immune responses when used in combination with other binding agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antibody-based therapies block the interaction between PD-1 and its ligands, then immune suppression is achieved, but T-cell activity is unintentionally suppressed
Solution Approach 1:
The patent segments the PD-1 binding site into two distinct regions: a ligand-binding site and a separate anchoring site. By targeting the anchoring site with single domain antibodies, the invention allows PD-1 to remain engaged with its ligands while simultaneously providing a attachment point for therapeutic molecules, thus separating the functions of ligand interaction and therapeutic anchoring.
Solution Approach 2:
The single domain antibodies act as intermediary molecules that bind to the anchoring site on PD-1 without interfering with the ligand-binding site. These intermediaries provide a platform for delivering therapeutic effects while allowing the PD-1 ligand interaction to proceed normally, thus mediating between the need for immune suppression and the need to maintain T-cell activity.
2Reliability
If PD-1 interaction with ligands is blocked, then immune checkpoint inhibition is achieved, but unintended suppression of T-cell proliferation and cytokine response occurs
Solution Approach 1:
The patent applies local quality by creating a specific binding interface at the anchoring site that is spatially separated from the ligand-binding site. This localized binding allows the single domain antibodies to provide therapeutic anchoring functionality without altering the local dynamics of the ligand-binding site, thereby preserving T-cell proliferation and cytokine response while maintaining immune checkpoint inhibition.
3Reliability
If conventional antibodies are used to target PD-1, then therapeutic effect is achieved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts only the variable domain (single domain antibody) from the full antibody structure, removing the constant regions and light chains. This extraction simplifies the molecular structure, reduces manufacturing complexity, and enables easier production while maintaining the ability to bind to the anchoring site on PD-1 and provide therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VH sdAbs increase the inhibitory effect by 10 to 25-fold when used in a bivalent format with blockers, providing a targeted approach to modulate immune responses without suppressing T-cell activity, and can be used in combination with other antibodies or immunomodulators to enhance therapeutic outcomes.
Implementation Method 1
human variable single domain antibodies (VH sdAbs) that bind to PD-1 without blocking its interaction with PD-L1 and PD-L2
Data Source
AI summary
The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.